Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review

Abstract

Therapeutic drug monitoring (TDM) receives growing interest in different psychiatric clinical settings (emergency, inpatient, and outpatient services). Despite its usefulness, TDM remains underemployed in mental health. This is partly due to the need for evidence about the relationship between drug serum concentration and efficacy and tolerability, both in the general population and even more in subpopulations with atypical pharmacokinetics. This work aims at reviewing the scientific literature published after 2017, when the most recent guidelines about the use of TDM in mental health were written. We found 164 pertinent records that we included in the review. Some promising studies highlighted the possibility of correlating early drug serum concentration and clinical efficacy and safety, especially for antipsychotics, potentially enabling clinicians to make decisions on early laboratory findings and not proceeding by trial and error. About populations with pharmacokinetic peculiarities, the latest studies confirmed very common alterations in drug blood levels in pregnant women, generally with a progressive decrease over pregnancy and a very relevant dose-adjusted concentration increase in the elderly. For adolescents also, several drugs result in having different dose-related concentration values compared to adults. These findings stress the recommendation to use TDM in these populations to ensure a safe and effective treatment. Moreover, the integration of TDM with pharmacogenetic analyses may allow clinicians to adopt precise treatments, addressing therapy on an individual pharmacometabolic basis. Mini-invasive TDM procedures that may be easily performed at home or in a point-of-care are very promising and may represent a turning point toward an extensive real-world TDM application. Although the highlighted recent evidence, research efforts have to be carried on: further studies, especially prospective and fixed-dose, are needed to replicate present findings and provide clearer knowledge on relationships between dose, serum concentration, and efficacy/safety.

Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis

“…In lamotrigine's case, the epileptic and psychiatric population differed substantially, the psychiatric reports included 2.5 times more concomitant medications with cardiac adverse events, and 1.5‐fold more reports on overdose and suicide attempts. In addition, lamotrigine plasma monitoring is usually the standard of care in the epileptic population but it is still gaining popularity in the psychiatric population 16 . Hence we illustrate the importance of examining signals for the epileptic and psychiatric indications separately.…”

“…In addition, lamotrigine plasma monitoring is usually the standard of care in the epileptic population but it is still gaining popularity in the psychiatric population. 16 Hence we illustrate the importance of examining signals for the epileptic and psychiatric indications separately.…”

Pharmacogenomic Diversity in Psychiatry: Challenges and Opportunities in Africa

“…This suggests that the presence of genetic variation within African populations, which could affect drug metabolism, clearance, and potentially determine treatment outcomes (82). This highlights the significance of therapeutic drug monitoring (TDM) in optimizing pharmacotherapy for psychiatric patients in Africa (94). TDM offers the opportunity to leverage individual variability of antidepressant pharmacokinetics to shed light on non-response and partial response, evaluate adherence, and characterize the impact of genetic and developmental variation in pharmacokinetic genes (95).…”

Towards Precision Medicine in Clinical Practice: Alinity C vs. UHPLC-MS/MS in Plasma Aripiprazole Determination

“…In recent years, an increasing body of literature has emphasized the significance of personalized medicine in psychiatric care, highlighting the importance of tailoring treatments based on individual patient profiles [ 6 , 7 , 8 ]. The advent of precision psychiatry has underscored the need for robust analytical methods capable of delivering accurate and reliable data for informed decision-making in the clinical setting [ 9 , 10 ]. In this regard, achieving optimal therapeutic outcomes of aripiprazole requires the precise monitoring of plasma concentrations.…”